Xenon Pharmaceuticals (XENE) Equity Ratio (2013 - 2026)

Xenon Pharmaceuticals (XENE) has 14 years of Equity Ratio data on file, last reported at 0.96 in Q1 2026.

• Equity Ratio for Q1 2026 came in at 0.96, up 1.86% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.96 (up 1.86% YoY), and the FY2025 annual result was 0.92, down 2.86% from the prior year.
• Equity Ratio rose to 0.96 in Q1 2026 per XENE's latest filing, from 0.92 in the prior quarter.
• Over five years, Equity Ratio peaked at 0.97 in Q2 2022 and troughed at 0.92 in Q4 2025.
• A 5-year average of 0.95 and a median of 0.95 in 2024 frame the typical range for Equity Ratio.
• The sharpest annual moves came in 2022 and 2025: Equity Ratio advanced 4.04% in 2022, then dropped 3.56% in 2025.
• A 5-year view of Equity Ratio shows it stood at 0.96 in 2022, then advanced by 0.53% to 0.96 in 2023, then declined by 1.66% to 0.95 in 2024, then declined by 2.86% to 0.92 in 2025, then grew by 4.99% to 0.96 in 2026.
• Business Quant data shows XENE's Equity Ratio at 0.96 in Q1 2026, 0.92 in Q4 2025, and 0.92 in Q3 2025.